Health insurance possible for Herceptin in minor breast cancer patients

Published: 2010-10-22 06:59:00

Updated: 2010-10-22 06:59:00

In the case of Roche’s Herceptin (trastuzumab), the government is set to expand its support for patients suffering from earlier stage breast cancer who have not shown any metastasis in lymph node but with tumor size of more than 1 cm.

Trastuzumab is a monoclonal antibody that interferes with t...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK